# Rt-PA in the Treatment of Acute Ischemic Stroke

> **NCT00153036** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 821 (actual)

## Conditions studied

- Cerebrovascular Accident

## Interventions

- **DRUG:** rt-PA 0.9 mg/kg verum or placebo Intravenous

## Key facts

- **NCT ID:** NCT00153036
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2008-02
- **Final completion:** —
- **Target enrollment:** 821 (ACTUAL)
- **Last updated:** 2014-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00153036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00153036, "Rt-PA in the Treatment of Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00153036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*